key: cord-0984024-tbtet9qn
authors: Message, Simon D.; Johnston, Sebastian L.
title: Infections
date: 2009-01-30
journal: Asthma and COPD
DOI: 10.1016/b978-0-12-374001-4.00037-7
sha: b95529a1689ec87322971e9b8fbf3c3a6981d00b
doc_id: 984024
cord_uid: tbtet9qn

This chapter reviews the epidemiological evidence implicating infectious pathogens as triggers and will discuss the mechanisms of interaction between the host–pathogen response and preexisting airway pathology that result in an exacerbation. Asthma is a multifaceted syndrome involving atopy, bronchial hyperreactivity, and IgE and non-IgE-mediated acute and chronic immune responses. The asthmatic airway is characterized by an infiltrate of eosinophils and of T-lymphocytes expressing the type 2 cytokines IL-4, IL-5, and IL-13. Trigger factors associated with acute exacerbations of asthma include exposure to environmental allergens, especially animals, molds, pollens and mites, cold, exercise, and drugs. The frequency of exacerbations is a major factor in the quality of life of patients with COPD. The typical clinical features of an exacerbation include increased dyspnea, wheezing, cough, sputum production, and worsened gas exchange. Although noninfectious causes of exacerbations such as allergy, air pollution, or inhaled irritants including cigarette smoke may be important, acute airway infections are the major precipitants. The infection and consequent host inflammatory response result in increased airway obstruction. The success of vaccination to prevent respiratory virus infections has been limited by significant variation within the major virus types causing disease. Currently much of the treatment of infective exacerbations of asthma and COPD is symptomatic, consisting of increased bronchodilators, either short-acting β 2—agonists in inhaled or intravenous form or anticholinergics or theophyllines, or supportive in the form of oxygen and in severe cases noninvasive or invasive ventilatory measures.

Asthma and chronic obstructive pulmonary disease (COPD) are common diseases and both result in signifi cant morbidity and mortality. Although they share some clinical features and although they may coexist in the same individual, they are distinct disease syndromes with diff erent pathogenetic mechanisms. In each case much of the morbidity and mortality is associated with exacerbations of disease, in response to a variety of trigger factors. A common feature of asthma and COPD is the important role of infection in triggering exacerbations. Infections have also been implicated in the etiology of the two diseases. Th is chapter will review the epidemiological evidence implicating infectious pathogens as triggers and will discuss the mechanisms of interaction between the host-pathogen response and preexisting airway pathology that result in an exacerbation.

Asthma aff ects 20-33% of children in the United Kingdom [1] . It is a multifaceted syndrome involving atopy, bronchial hyperreactivity, and IgE and non-IgE-mediated acute and chronic immune responses. Th e asthmatic airway is characterized by an infi ltrate of eosinophils and of T-lymphocytes expressing the type 2 cytokines IL-4, IL-5, and IL-13. Trigger factors associated with acute exacerbations of asthma include exposure to environmental allergens, especially animals, molds, pollens and mites, cold, exercise, and drugs. Th e link between respiratory infection and asthma exacerbations is well established although incompletely understood. In the 1950s this association was attributed to bacterial allergy [2] but it is now clear that the majority of exacerbations are due to viral rather than bacterial infection.

Viral respiratory tract infections are a major cause of wheezing in infants and in adult patients with asthma. Th eir role may have been underestimated in early epidemiological studies because of diffi culties in isolation and identifi cation [3] . Th e introduction of PCR to such studies has implicated viral infection in the majority of asthma exacerbations.

Indirect evidence from population studies has established a signifi cant correlation between the seasonal variation in wheezing episodes in young children and peaks of virus identifi cation [4] . Seasonal patterns of identifi cation of respiratory viruses are associated with peaks in hospital admissions for both children and adults with asthma indicating a role for such infections in severe asthma attacks [5] . Direct evidence implicating viral infection in asthma exacerbations has been provided by studies showing an increased rate of virus detection in individuals suff ering asthma attacks. Viruses have been detected in 80-85% of asthma exacerbations in children [4] [5] [6] [7] [8] [9] [10] and in 75-80% in adults [11] [12] [13] [14] . Th e highest rates of identifi cation are in those studies where subjects were followed prospectively allowing collection of clinical specimens early in the course of the illness, where PCR-based methods of diagnosis were used instead of or in addition to serology and culture, and where the methodology used allowed for detection of rhinoviruses. Th e rate of detection of viruses between exacerbations when individuals are asymptomatic is only of the order of 3-12%. In contrast a study of transtracheal aspirates in adult asthmatics during exacerbations [15] yielded sparse bacterial cultures with no correlation to clinical illness and no diff erence from those of normal subjects.

In almost all studies of asthmatics, the predominant viruses are rhinoviruses (RV), infl uenza, RSV, and parainfl uenza viruses. RV alone are detected in around 50% of virus-induced asthma attacks. Adenoviruses, enteroviruses, metapneumoviruses, bocaviruses, and coronaviruses are also detected but less frequently. Infl uenza is only found during annual epidemics.

Th e eff ects of respiratory virus infection in the nasal mucosa and upper respiratory tract have been extensively investigated. Th e eff ects of such viruses in the lower respiratory tract have been studied but detailed knowledge of the pathogenetic mechanisms involved in asthma exacerbations remains limited. Experimental respiratory virus infection in human volunteers is limited to mild disease by concerns of safety [16] . Most such studies have therefore focused on the experimental innoculation of rhinovirus in allergic rhinitic or mild asthmatic individuals and normal control subjects [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Such studies provide a useful model of natural virus infection in asthma and off er the advantages of patient selection and monitoring, under controlled conditions before, during, and after infection, of administration of active and placebo medication, of ability to sample the lower airway with timing from onset of infection accurately defi ned and the study of RV-induced eff ects including asthma symptomatology, lung function, and airway pathology/immunology. Recent epidemiological evidence confi rms a synergistic interaction between virus infection and allergen exposure in precipitating hospital admissions for asthma [29, 30] . Other trigger factors that may interact with infection include air pollution. A study of asthmatic children demonstrated an increased risk of developing an asthmatic episode within 7 days of an upper respiratory tract infection if the nitrogen dioxide level was greater than 28 μ g/m 3 [9, 31] .

Most studies of experimental virus infection in allergic subjects are performed outside the relevant season for allergen exposure. One attempt to provide a model combining allergen exposure and virus infection utilized RV infection in subjects with allergic rhinitis. Individuals received three high dose allergen challenges in the week prior to innoculation to try to mimic combined allergen exposure and virus infection [32] . Interestingly, prior allergen challenge in this model, somewhat unexpectedly, appeared to protect against an RV cold with delayed nasal leukocytosis, increased generation of the proinfl ammatory cytokines IL-6 and IL-8 and a delayed, less severe clinical course. Th ere was an inverse correlation between nasal lavage eosinophilia and the severity of cold symptoms. Th e explanation proposed by the authors of this study is that limited high dose allergen challenge may not reproduce the eff ects of chronic low dose allergen exposure and may stimulate the production of antiinfl ammatory mediators such as IL-10 or antiviral cytokines such as IFN-γ or TNF-α . In work by de Kluijver et al . the eff ects of a 10-day period of low dose allergen exposure in house-dust mite sensitive and/or experimental RV16 infection were studied. No synergistic or additive eff ects were observed as regards lung function parameters [33] . Further development of models of experimental combined allergen exposure and virus infection is clearly required.

We have recently adopted the approach of infecting asthmatic volunteers with RV and then sending them home to continue their normal allergen exposure in the natural environment [34] . We investigated physiologic, virologic, and immunopathologic responses to experimental rhinovirus infection in blood, induced sputum, and bronchial lavage in 10 atopic mild asthmatic and 15 nonatopic normal volunteers. Rhinovirus infection induced significantly greater lower respiratory symptoms, lung function impairment, increases in bronchial hyperreactivity, and eosinophilic lower airway infl ammation in asthmatic compared to normal subjects. We also saw trends to increased neutrophils and lymphocytes in the lower airway in asthmatics, and coincident reductions in blood lymphocytes, suggesting traffi cking to the airway. In asthmatic, but not normal subjects, virus load was signifi cantly related to lower respiratory symptoms, bronchial hyperreactivity, and reductions in blood total and CD8 ϩ lymphocytes and lung function impairment was signifi cantly related to neutrophilic and eosinophilic lower airway infl ammation. Th is study demonstrated increased rhinovirus-induced clinical illness severity in asthmatic compared to normal subjects, provided evidence of strong relationships between virus load, lower airway virus-induced infl ammation, and asthma exacerbation severity and suggests that this approach could provide a very good model in which to examine asthma exacerbation pathogenesis as well as treatment interventions.

Whereas other respiratory viruses such as infl uenza, parainfl uenza, RSV, and adenovirus are well recognized causes of lower airway syndromes such as pneumonia and bronchiolitis and are capable of replication in the lower airway, until recently there was uncertainty as to whether RV infection occurred in the lower airway or solely in the upper respiratory tract . Although the possibility of nasopharyngeal contamination cannot be ruled out, RV has been detected in lower airway clinical specimens such as sputum [35] , tracheal brushings [26] , and BAL [36] by both RT-PCR and culture. RV has been cultured in cell lines of bronchial epithelial cell origin [37] and replication has been demonstrated in primary cultures of bronchial epithelial cells [38] [39] [40] . Th e preference of RV for culture at 33°C rather than 37°C has been used as an argument against lower airway infection but there is now evidence that replication does occur at lower airway temperatures [41] . Finally the use of in situ hybridization has conclusively demonstrated RV replication in bronchial biopsies of subjects following experimental infection [38] and recent immunochemistry data suggests a preference for basal cells [42] . Th ese data confi rm that RV infection of the lower airway does occur and directly implicate lower airway infection in the pathogenesis of asthma exacerbations.

Investigation into the pathogenesis of rhinovirus infections and rhinovirus-induced asthma exacerbations has been severely hampered for the ϳ 50 years since their discovery, as it has been believed that rhinoviruses only infect humans and chimpanzees. However, a mouse model of rhinovirus infection has recently been successfully developed for the fi rst time. New methods of purifi cation and concentration of rhinoviruses, were used to show that for the minor group of rhinoviruses (the ϳ 10% that use the LDL receptor as their mode of entry into cells), wild-type BALB/c mice can be successfully infected and that most of the diseaserelated outcomes observed in humans were reproduced in this unique new model. Th ese outcomes include induction of both innate and acquired immune responses, induction of mucin synthesis and secretion, induction of both acute neutrophilic and prolonged lymphocytic airway infl ammation, and induction of chemokines responsible for chemoattraction of neutrophils, lymphocytes and dendritic cells as well as a range of proinfl ammatory cytokines. Mice transgenic for a chimera of ICAM-1, the receptor for the major group ( ϳ 90%) of rhinoviruses, in which the rhinovirusbinding domains were human, but the remainder of the molecule mouse were then developed. Th is transgenic mouse was then able to be infected by major group strains, thus generating mouse models capable of being infected by all rhinovirus serotypes. Finally an established mouse model of allergic airway infl ammation was used to demonstrate that rhinovirus infection of this model resulted in rhinovirusinduced exacerbation of allergic airway infl ammation. Th e asthma-related outcomes exacerbated by infection in this model include exacerbation of airway hyperresponsiveness, exacerbation of mucin synthesis and secretion (MUC5AC and MUC5B), exacerbation of neutrophilic, eosinophilic, and lymphocytic airway infl ammation, and augmented induction of both Th 1 (IFN-γ ) and Th 2 (IL-4 and -13) cytokines. Th e development of this novel mouse model of rhinovirus-induced asthma exacerbations, should allow mechanisms of disease to be investigated in vivo and true causation be established in vivo . [43] .

Subjects with asthma and/or allergic rhinitis exhibit increased pathophysiological eff ects as a result of RV infection as compared to nonatopic, nonasthmatic controls. With detailed monitoring, it is possible to detect reductions in both peak fl ow [44] and home recordings of FEV 1 [24] in atopic asthmatic patients in the acute phase of experimental RV16 infection. Th ere is an enhanced sensitivity to histamine and allergen challenge after RV16 innoculation in nonasthmatic atopic rhinitic subjects [19, 45] . RV16 increases asthma symptoms, coinciding with an increase in the maximal bronchoconstrictive response to methacholine up to 15 days after infection [20] . Th ere is also a signifi cant increase in sensitivity to histamine in asthmatic subjects after RV16 infection, most pronounced in those with severe cold symptoms [25] and our recent study confi rmed that these reductions in lung function and increases in symptoms and airway hyperresponsiveness were observed only in asthmatic, but not in normal subjects [34] .

Current concepts of a typical antiviral immune response, as reviewed in detail elsewhere [46, 47] , result from research in human volunteers and patients but also in experimental animals, especially inbred mice. Results of animal studies may not be directly applicable to the outbreed human population but ethical considerations often limit direct investigation of the human immune system. All immune responses are a combination of nonspecifi c (innate) and specifi c (adaptive) immunity.

Nonspecifi c or innate [48] elements include: phagocytes such as neutrophils and macrophages that engulf and destroy viruses; natural killer (NK) cells that recognize and destroy virus-infected cells on the basis of reduced HLA class I expression; cells including NK cells, neutrophils, macrophages, mast cells, basophils, epithelial cells that release cytokines, such as interferons, with immunoregulatory or antiviral actions; components of body fl uids such as complement, defensins, and surfactant proteins that are capable of neutralizing viruses independently of, or in combination with, antibodies.

Some viruses may also cause complement-mediated damage. Complement components bind to epithelial cells both in vitro and in vivo during RSV infections. C3a and C5a are increased in human volunteers infected with infl uenza A virus [49] . Th ere is little information on the role of complement in immunity to RV. Recent data suggests that the RV 3C protease cleaves the complement factors C3 and C5 which may interfere with the destruction of virus-infected cells [50] . For other viruses, for example infl uenza, the complement system forms an important link between the innate and specifi c immune systems. Mice defi cient for the third component of complement are highly susceptible to primary infl uenza, showing reduced priming of T-helper cells and cytotoxic T-cells in lung draining lymph nodes and severely impaired recruitment into the lung of virus-specifi c CD4 ϩ and CD8 ϩ eff ector T-cells producing IFN-γ [51] . Activation of the complement cascade may be necessary for the function of other innate antiviral proteins such as serum mannose-binding protein [52] Defensins Th e α and β defensins are small cationic antimicrobial peptides which have the capacity to kill bacteria, fungi, and enveloped viruses by disruption of the microbial membrane.

In vivo they are probably most important in phagocytic vacuoles and on the surface of skin and mucosal epithelia. In addition to their direct antibiotic role, defensins are increasingly being found to have immunomodulatory actions [53] and to play a role in cell recruitment through activation of certain chemokine receptors, for example hBD3 and CCR6 on dendritic cell (DC).

Specifi c immunity involves production of antibody by B-lymphocytes and the activities of cytotoxic T-cells following processing and presentation of viral antigens by additional cells of the immune system, the most important of which are probably dendritic cells. Immunological memory modifi es the overall response to reinfection by previously encountered virus and alters the timing and magnitude of contributions due to diff erent components.

In primary infection, viruses replicate in the respiratory tract reaching peak levels at around days 2-4. At this time type I interferons are fi rst detected, peaking around days 2-3 and falling to become undetectable once active replication has ceased. Interferons activate NK cells, fi rst detectable around day 3 and peaking around day 4. In addition to destruction of virally infected cells NK cells release cytokines including IFN-γ that activate additional infl ammatory cells in the airway including macrophages. Such nonspecifi c immune mechanisms are essential in early defense against virus in the fi rst few days. In addition, the innate immune system plays a role in stimulating specifi c immunity and may infl uence the nature of the specifi c response, for example whether this is characterized by type 1 or type 2 cytokines.

Meanwhile, viral antigens are processed locally and in regional lymph nodes by dendritic cells and presented to T-cells. CD4 ϩ and CD8 ϩ T-cells are detectable from around day 4 then generally decline as infection resolves to become undetectable by day 14. However, memory CD4 ϩ and CD8 ϩ responses may persist for life. T-cell recruitment is dependent on the production of chemokines and on alterations in the expression of adhesion molecules on the endothelium of infl amed tissues. Time is also required to generate B-cell responses. Mucosal IgA may be detected around day 3, serum IgM from days 5-6 and IgG days 7-8, increasing in amount and avidity over the next 2-3 weeks. IgA falls normally to low or undetectable levels over 3-6 months. Serum IgG may remain detectable for life. Specifi c immune mechanisms such as CD8 ϩ T-cells and immunoglobulin are responsible for the eradication of infectious virus usually by 7-10 days after infection.

Secondary infection with the same virus results in rapid mobilization of B-and T-cell specifi c immunity with an earlier T-cell peak coinciding with the NK cell peak around days 3-4. If reinfection is with the same serotype a rapid increase in levels of preexisting neutralizing antibodies may limit viral replication to such an extent that infection is clinically silent. Because this results in fewer infected cells there is relatively less activation of nonspecifi c immunity and it may be diffi cult to detect a CD8 ϩ T-cell response.

Following experimental infection of seronegative subjects with RV2 [54] serum-specifi c antibodies are detectable at 1-2 weeks, reach a maximum at 5 weeks, persist for at least a year and may remain elevated many years after infection. Local specifi c antibody levels may be lost more rapidly. High levels of serum neutralizing antibody or specifi c IgA protect against reinfection with the same rhinovirus serotype. However, since it appears relatively late, recovery from illness for seronegative hosts which usually occurs at 7-10 days must be due to other components of the immune response. In seropositive subjects preexisting serum neutralizing antibodies to RV39 and to RV-Hanks modify experimental infections in human subjects [55, 56] . Local IgA and IgG passing from the vasculature into the pulmonary interstitium contribute to viral clearance. However, the 100 ϩ RV serotypes mean that repeated infection with RV to which an individual lacks appropriate antibodies is common .

T-cell responses to RV demonstrate MHC class I restricted cross-reactivity between serotypes due to specificity for conserved epitopes within the capsid proteins VP 1-3 [57] . RV16-and RV49-specifi c T-cell clones from human peripheral blood demonstrate recognition of both serotype specifi c and shared viral epitopes [58] . Vigorous proliferation of and IFN-γ production by PBMC in response to RV16 in seronegative subjects is associated with reduced viral shedding after inoculation [59] , thus T-cells responses also appear protective.

Th e interaction of respiratory virus infection and chronic asthmatic airway infl ammation results in respiratory symptoms that are more severe than those suff ered by nonasthmatic individuals [34, 60] and case-control studies have demonstrated clear synergistic interactions between virus infection and allergen exposure in increasing risk of exacerbation [29, 30] . Th e detailed immunological mechanisms underlying this interaction are currently being investigated, but recent data suggest defi cient production of type I ( β ), type II ( γ ), and type III ( λ ) IFNs, as well as Th 1 cytokines (IL-12) and anti-infl ammatory cytokines (IL-10), are likely to increase virus-induced lower airway infl ammation [34, 61, 62] . Th ese defi ciencies are also accompanied by augmented production of Th 2 cytokines suggesting that perhaps allergen-induced infl ammation is also increased in the pathogenesis of virus-induced asthma exacerbations.

Bronchial infl ammation is likely therefore a central event for virus-induced asthma exacerbations. Th e processes involved include interacting cascades from the complement, coagulation, fi brinolytic, and kinin systems of the plasma as well as cell-derived cytokines, chemokines, and arachidonic acid metabolites. Our understanding of the interaction of viruses with these cascades in asthma is incomplete and it is likely that diff erent viruses interact with each system to diff erent extents. However, it is reasonable to believe that in all cases the initial trigger of the infl ammatory reactions is epithelial cell-virus interaction. 

Th e airway epithelium is an important component of antiviral defense. In addition to its function as a physical barrier to the entry of viruses, the responses of epithelial cells (EC) following viral infection, whether or not this results in destruction of the cell, contribute to both innate and adaptive antiviral immune responses. Information regarding the eff ects of RV on EC comes from in vivo studies and from in vitro models using either cultured primary airway EC or cell lines of epithelial cell origin such as A549, BEAS-2B, and H292.

EC contribute to the immune response following virus infection through the production of cytokines and chemokines ( Fig. 37 .1 ). Th ey may also act as antigen presenting cells particularly during secondary respiratory viral infections. Epithelial cells express MHC class I and the costimulatory molecules B7-1 and B7-2 and this expression is upregulated in vitro by RV16 [63] ( Fig. 37.2 ) .

Th e extent of epithelial cell destruction observed in the airway varies according to virus type. Infl uenza typically causes extensive necrosis [64] , whereas RV causes little or only patchy damage. Destruction of epithelial cells results in both an increase in epithelial permeability, and increased penetration of irritants and allergens, and exposure of the extensive network of aff erent nerve fi bers. Both eff ects may contribute to increased bronchial hyperresponsiveness. In vivo RV causes some shedding of infected ciliated EC [65] , but the extent of viral infection of the epithelium may be incomplete even in the nose [66] . In vitro studies exposing monolayer cultures of nasal epithelial cells to respiratory viruses at 10 3 -10 4 TCID 50 /ml demonstrate no detectable CPE (carboxypeptidase E) with RV or coronavirus in contrast to the extensive destruction with infl uenza and adenovirus [67] . Ex vivo infection of cells from both the upper and the lower respiratory tract suggest that less than 10% of cells in the epithelium are infected by RV [68] , however the extent of virus-induced epithelial damage may be considerably greater in asthmatic than in normal subjects, as asthmatic epithelium has been shown to be much more susceptible in vitro [61] . In vivo studies of degrees of epithelial damage would be technically challenging, but could generate interesting fi ndings.

Viruses enter into and replicate within airway EC. Entry is dependent on the interaction with host cell surface proteins which function as receptors. In the case of the major group RV this is ICAM-1 [69] and infection can be blocked by antibodies to ICAM-1 or with soluble ICAM-1 [37] . Th ere is relatively limited expression of ICAM-1 in airway epithelium prior to RV infection [70] and this may explain the patchy nature of infection. Th e upregulation of ICAM-1 in the asthmatic airway is one possible explanation for the increased severity of RV infection in asthma. RV upregulates expression of its own receptor ICAM-1 both in vitro and in vivo . Following experimental infection with RV, ICAM-1 expression is upregulated in nasal epithelium within 24 h, declining by day 5 [71] . RV has similar eff ects on EC from the lower airway. RV has been shown to upregulate ICAM-1 in primary bronchial EC in vitro [72] and ICAM-1 is upregulated in bronchial biopsies following experimental infection of asthmatic subjects with RV16 [73] .

Th ere are two forms of ICAM-1: membrane bound (mICAM-1) which favors viral infection by acting as a virus receptor and soluble (sICAM-1) which binds virus outside the cell and can thereby inhibit virus infection. RV infection of EC is reported to alter the balance in favor of further infection by inducing mRNA for mICAM-1 whilst suppressing that of sICAM-1 [74] . Th e LDL receptor is the receptor for the minor group RV. RV2 infection of primary human tracheal EC (PHTEC) is blocked by an antibody to the LDL receptor and is also reported to upregulate LDL-R expression [48] .

ICAM-1 expression by human nasal EC is upregulated in vitro by exposure to a number of infl ammatory cytokines and mediators including IL-1 β , IL-8, IFN-γ , TNF-λ , and the eosinophil-derived proteins MBP and ECP [75] . IL-1 β in particular may be important in RV-induced induction of ICAM-1. Antibodies to IL-1 β but not TNF-α decreased viral replication and ICAM-1 expression by PHTEC [76] . Not all respiratory epithelial cell lines behave in the same way as primary EC -for example A549 cells express ICAM-1 at lower levels constitutively and show upregulation by IFN-γ and TNF-α but not by ECP or MBP. Th e eff ect of IFN-γ is complex. Whilst IFN-γ upregulates ICAM-1 in uninfected cells this cytokine inhibits ICAM-1 upregulation by RV14 in H292 cells and its presence results in reduced viral titers [72, 77] . A preexisting elevation of ICAM-1 expression in the asthmatic airway may contribute to increased symptom severity of RV infection. Type 2 cytokines (IL-4, IL-5, IL-13) upregulate ICAM-1 in H-292 cells [78] . Allergen challenge results in upregulation of ICAM-1 on conjunctival and nasal EC in atopics [79] . In nasal brushing EC from atopics, basal ICAM-1 levels were increased relative to nonatopics and elevated in the relevant allergen season. Nasal EC from atopics showed further upregulation after in vitro culture with allergen. Th e highest basal ICAM-1 was found on nasal polyp EC and this was increased further after RV14 infection. Viral titers after RV14 infection were signifi cantly higher for polyp EC than for nonatopic and atopic nonpolyp EC [80] .

Modifi cation of EC ICAM-1 expression is therefore of possible therapeutic benefi t. In vitro RV increases expression of ICAM-1 and VCAM-1 in primary bronchial EC (PBEC) cultures and in A549 cells via a mechanism involving NF-κ B [5, 81, 82] . One of the actions of corticosteroids is inhibition of NF-κ B [83] . In both A549 cells and in PBEC pretreatment with three corticosteroids, hydrocortisone, dexamethasone, and mometasone furoate inhibits RV16-induced increases in ICAM-1 surface expression, mRNA, and promoter activation without alteration of virus infectivity or replication. Dexamethasone suppresses ICAM-1 in PHTEC and inhibits RV infections [84] . Dexamethasone does not inhibit infection of PHTEC by minor group RV2 [85] . Disappointingly, a study of inhaled corticosteroids in asthmatics prior to experimental RV infection failed to show reduced virus-induced ICAM-1 expression in bronchial biopsies [73] but it is possible that a longer course and/or a higher dose of inhaled steroid or administration of oral steroids might have demonstrated a signifi cant eff ect.

Other drugs which aff ect EC ICAM-1 include reducing agents [86] , the H 1 receptor antagonists desloratidine/ loratidine which inhibit RV-induced ICAM-1 upregulation in HPBEC and in A549 cells [87] and erythromycin which inhibits infection of PHTEC by both major group RV14 and minor group RV2 through eff ects including ICAM-1 reduction, blockage of RV RNA entry into endosomes and small reductions in LDL receptor expression [88] .

EC can activate and recruit a variety of other cell types such as lymphocytes, eosinophils, and neutrophils through the production of chemokines and cytokines ( Fig. 37.1 ). Such cells are important components of the antiviral response but may also contribute to airway infl ammation and dysfunction in asthma.

Interferons (IFN) play an important role in innate resistance to viruses [89] , acting on virus-infected cells and surrounding cells to produce an antiviral state characterized by the expression and antiviral activity of IFN-stimulated genes (ISGs). Th ere are three main types of IFN, type 1 (IFN-α , IFN-β , IFN-ω , IFN-τ ), type 2 (IFN-γ ) and the recently discovered type 3 (IFN-λ s [90, 91] ). EC can produce both type 1 and type 3 IFNs. Th ere are 14 IFN-α genes but only 1 IFN-β gene. IFN-β synthesis involves NFκ B, ATF/JUN and the interferon regulatory factors (IRFs) (up to 10 of which are currently identifi ed), activation of which occurs in response to virus-specifi c signals including dsRNA, a product of the replication of ssRNA viruses such as RV, RSV, and infl uenza.

IFN-β and IFN-α 4 are expressed early through the action of IRF3. Activation of the IFN intracellular signaling pathway is required for induction of IRF7 which is required for transcription of the full range of IFNs. DNA microarray analysis has shown that following binding to their receptors on target cells IFNs trigger a complex signaling pathway (mainly JAK-STAT) resulting in the transcription of hundreds of ISGs [92] .

Several ISGs have been well studied. Th ese include the dsRNA-activated serine/threonine protein kinase (PKR) which reduces cellular mRNA translation and transcriptional events, two enzymes involved in mRNA degradation, 2 Ј 5 Ј oligoadenylate synthetase (OAS) and RNase L, the myxovirus resistance (Mx) proteins and RNA-specifi c adenosine deaminase (ADAR) which is involved in RNA editing. Th ese ISGs inhibit virus replication at a number of levels and not surprisingly, viruses have evolved mechanisms to resist the actions of IFNs, for example blocking of PKR by the infl uenza NS1 protein [93] . IFNs also upregulate cellular expression of MHC class I and II molecules therefore increasing antigen presentation to CD8 ϩ and CD4 ϩ T-cells and enhancing cellular immune responses.

One recent study has examined type 1 interferon production by primary bronchial epithelial cells from normal and asthmatic subjects infected ex vivo with RV [40] . Asthmatic EC following infection released a higher titer of virus into culture supernatant and exhibited impaired apoptosis and a greater degree of necrotic cell death, favoring release of virus from dying cells. Th is was accompanied by lower concentrations of IFN-β after infection. Addition of IFN-β to asthmatic ECs inhibited virus replication to levels observed in ECs from normal subjects. Th is study suggests that the production of IFN-β is defi cient in asthmatic ECs and that replacement/augmentation of IFN-β to boost the innate immune response could be a novel approach to treatment of virus-induced asthma exacerbations [94] .

A new family of interferons, called type III IFN-λ s, and characterized by three elements: λ 1, λ 2, and λ 3, also termed IL-29, IL-28A, and IL-28B, has recently been described [90, 91] . Th e three highly homologous IFN-λ proteins demonstrate limited (about 20%) homology to type I IFNs [95] . Human IFN-λ s bind to a unique heterodimeric receptor (IFN-λ R), composed of CRF2-12 (also designated IFN-λ R1), and CRF2-4 (also designated IL-10R2) shared with other class II cytokine-receptor ligands including IL-10, IL-22, and IL-26 [90] .

Viral infection induces upregulation of IFN-λ mRNA in epithelial cells, peripheral blood mononuclear cells (PBMCs), and dendritic cells [90, 91, [96] [97] [98] [99] . IFN-λ s exhibit some similar biological properties to type I IFNs: they induce Jak/STAT pathways that lead to the upregulation of several antiviral proteins and enzymes including 2 Ј ,5 Ј -OAS and MxA, have antiviral activity in vitro [90, 91, 97] and have also exhibited antviral activity in an in vivo model of vaccinia virus-infected mice [100] . Based on current knowledge, it thus appears that both IFN-α /-β and IFN-λ ligand-receptor systems can independently induce an antiviral state by engaging similar participants of the antiviral response, though the signaling pathways involved in IFN-λ production are currently largely unknown. Recent data suggest that IFN-λ may be involved in antiviral responses against RV. In vitro RV infection of a bronchial epithelial cell line (BEAS-2B) led to IFN-λ production and this cytokine demonstrated a dose-dependent antiviral eff ect against RV [62] . Moreover, IFN-λ production occurred after in vitro infection of primary bronchial epithelial cells, macrophages, and BAL cells from healthy volunteers.

We have recently investigated the production of IFN-λ s in response to RV in primary bronchial ECs and in BAL cells (90% macrophages) from normal and asthmatic subjects [62] . Production of IFN-λ 1 and IFN-λ 2-3 was deficient in ECs and BAL cells from asthmatic subjects after in vitro RV infection and induction of IFN-λ s by RV infection of ECs was strongly inversely related to RV replication. To determine whether IFN-λ production was important in determining responses to RV infection in vivo , the same volunteers were then experimentally infected with RV16, the severity of symptoms and reductions in lung function were monitored and the virus load was determined in BAL. In vitro production of IFN-λ s by RV infection of BAL cells was strongly inversely correlated with both common cold symptoms and in vivo virus load and strongly positively correlated with severity of falls in lung function, in asthmatic and normal volunteers experimentally infected with RV16. Asthmatic patients, in whom in vitro IFN-λ production in BAL cells was signifi cantly lower than in normal subjects, exhibited increased common cold symptoms and reductions in lung function and virus load after in vivo RV16 infection. In marked contrast normal subjects had robust IFN-λ responses, less severe cold symptoms, lower virus load, and no signifi cant changes in lung function. Th ese results document the importance of IFN-λ in the host defense against RV infection in vitro and in vivo and indicate that defi cient IFN-λ production is likely to be important in the pathogenesis of virus-induced asthma exacerbations.

Viral infection of the respiratory tract results in significant changes in the pattern of cytokine expression by a number of cell types, by both cells of the immune system, which may be increased in number and activation status, and by cells often considered to be structural but which in fact contribute signifi cantly to the immune response such as EC. Effi cient orchestration of the immune response by cytokines is essential for eradication of virus. Modifi cation of cytokine expression in the airway may contribute to the increased severity of virus infection in asthma.

In vitro studies of bronchial EC lines or macrophages have demonstrated the production of a wide range of proinfl ammatory cytokines such as IL-1, IL-6, IL-11, IFN-α , IFN-γ , TNF-α , and granulocyte-macrophage colony stimulating factor (GM-CSF) and the chemokines IL-8, ENA-78, RANTES, and IP-10 and macrophage infl ammatory protein (MIP)-1 α in response to RV and RSV [37, [101] [102] [103] . In vivo these cytokines can be found in nasal lavage in association with RV infection [104] .

Th e specifi c roles of individual cytokines in the human lower airway during viral infection are not well understood, but increasing information is becoming available. Such cytokines and chemokines activate and recruit a variety of other cells including lymphocytes, eosinophils, and neutrophils. IL-1, TNF-α , and IL-6 share proinfl ammatory properties such as the induction of the acute phase response and the activation of both T-and B-lymphocytes. IL-1 enhances the adhesion of infl ammatory cells to endothelium, facilitating chemotaxis [105] . TNF-α is a potent antiviral cytokine but in vitro increases the susceptibility of cultured epithelial cells to infection by RV14 through upregulation of ICAM-1 [37] . IL-6 has been shown to stimulate IgA-mediated immune responses. IL-11 may also be important in virus-induced asthma [106] . It appears to cause bronchoconstriction by a direct eff ect on bronchial smooth muscle [102] . Production of this cytokine by human stromal cells in vitro is increased by RV14, RSV, and parainfl uenza type 3 but not by cytomegalovirus (CMV), herpes simplex virus (HSV)-2 or adenovirus. In vivo IL-11 is elevated in nasal aspirates from children with colds, levels correlating with the presence of wheezing.

Similarly the chemokine MIP-1 α is increased in nasal secretions during natural viral exacerbations of asthma [107] . Studies in MIP-1 α knock-out mice suggest that it mediates pneumonitis due to infl uenza [108] . Th e other chemokines IL-8 and ENA-78, will recruit and activate neutrophils, while RANTES and IP-10 will do the same for lymphocytes [103] .

Viral upregulation of cytokines and chemokines may be mediated through certain key transcription factors. Increases in IL-6 and IL-8 production by cultured epithelial cells due to RV was dependent on NF-κ B [82, 107, 109] and further upstream, protein kinase R (PKR)-mediated RV-induced RANTES, IL-8, and IL-6 [110] . Rhinovirus induction of IL-8 was shown to require IkappaB kinasebeta (IKK β ) and the transcription factor NF-IL-6 as well as NF-κ B. Similar observations have been made with regard to the induction of IL-1, -6, -8, -11, and TNF-α by RSV [111, 112] , thus the potential role of inhibition of NF-κ B in this context has generated considerable interest.

In addition to the induction of IL-1 α and IL-1 β RV infection results in substantial increases in IL-1ra both in vivo and in vitro . Th is is a relatively late eff ect, occurring 48-72 h after infection and may contribute to symptom resolution [113] .

A multitude of infl ammatory mediators are generated or act on the epithelial surface. Bradykinin, a-nine-amino acid peptide generated from plasma precursors as part of the infl ammatory process has been shown to be present in nasal secretions of RV-infected individuals [114] . Bradykinin given intranasally is able to reproduce some of the symptoms of the common cold such as sore throat and rhinitis [115] . Although the presence of kinins in the lungs of virus-infected individuals has not been reported they are present in both the upper and lower airways in allergic reactions [114] [115] [116] [117] [118] .

Nitric oxide (NO) is produced by diverse sources including epithelial, endothelial, and smooth muscle cells. In human airways NO appears to be important in relaxation of the human airway smooth muscle [119] . Nitric oxide (NO) may be important in a range of respiratory diseases [120] including asthma [121] and in virus infection [122] . NO is produced both by the constitutive enzymes, nitric oxide synthase (NOS)1, and NOS3 and by the inducible, calcium-independent NOS2 expressed by airway EC [123] and macrophages.

In asthma there is increased NOS2 expression and an elevated level of exhaled NO [124] that falls with corticosteroid therapy; the level of exhaled NO correlates with sputum eosinophilia and methacholine responsiveness [125] . In contrast in stable COPD, exhaled NO levels are not diff erent from normal subjects [126] although there may be an increase during exacerbations [127] . In fact in vitro cigarette smoke reduces cytokine-induced NOS2 mRNA expression in the LA-4 murine cell line, in A549 cells and in PHBEC [128] .

Th e relative importance of the benefi cial antimicrobial activity of NO versus the potentially disadvantageous suppression of IFN-γ may be dependent on the specifi c pathogen. NOS2 knock-out mice show an increased susceptibility to infections [129] , perhaps because release of NO may be important for NK cell-mediated target cell killing [130] . However NO may also possess antiviral activity. In vitro RV induces NOS expression in HPBEC [131] . Th ere is increased expression of NOS2 mRNA in cultured HPBEC after RV16 infection [132] . NO inhibits RV-induced production of IL-6, IL-8, and GM-CSF and viral replication in a human respiratory epithelial cell line [132, 133] . RSV also induces NOS2 and increases nitrite levels in supernatant from A549 cells, from HPBEC culture and in BAL fl uid from RSV-infected BALB/c mice, eff ects opposed by IL-4 and dexamethasone but unaff ected by IL-13 or IFN-γ [134] . Replication of RSV in Hep2 cells is inhibited following transfection with a retroviral construct containing NOS and this inhibition is abolished by the NOS inhibitor, NGmethyl-l -arginine [135] . Replication of infl uenza A and B in Mabin Darby kidney cells is severely impaired by the NO donor, S -nitroso-N -acetylpenicillamine [136] .

Overall there is evidence that in vivo increased lower airway NO production may be of benefi t in virus-induced asthma exacerbations. Work in a guinea pig model suggests that one mechanism for increased airway hyperresponsiveness during respiratory virus infection is through inhibition of NOS enzymes and a loss of NO-related relaxation of airway smooth muscle [137] . Studies of human asthmatics would also suggest that NO has a protective role in virusinduced exacerbations. Following experimental RV16 infection patients with the greatest increase in exhaled NO had smaller increases in histamine airway responsiveness [131] .

In experimental animals parainfl uenza virus-induced hyperreactivity correlates with a defi ciency in constitutive NO production [137] . Increased levels of exhaled NO are found in nonasthmatic volunteers following natural colds [138] as well as in asthmatic patients after experimental RV infection [131] . In the latter study, an inverse association between NO increase and worsening of airway hyperresponsiveness was demonstrated arguing in favor of a protective role for this substance. Th is is further supported by the observation that NO reduces cytokine production and viral replication in an in vitro model of RV infection [133] . Interestingly, studies of viral upper respiratory tract infections have failed to demonstrate an increase in nasal NO after experimental RSV, RV, and infl uenza infections [139] . In normal subjects experimental infl uenza infection increased oral NO 8 days postinfection but had no eff ect on nasal NO [140] . Th is raises the possibility that during respiratory virus infection induction of NO is selective for the lower respiratory tract.

Th e responses of airway EC to virus infection are consequences of the interactions between virus and the intracellular signaling pathways of the host cell [141] . Knowledge of the mechanisms involved for rhinoviruses is currently very limited. Activation of signaling pathways may be dependent on cell surface receptor (ICAM-1, LDL-R) binding or may occur during viral replication within the cell. Th e need for replicative virus is demonstrated by the inhibition of RV induction of EC cytokines after UV inactivation. One product of replication, common to ssRNA viruses such as RV and also RSV and infl uenza, is dsRNA, which has been shown to activate components of signaling pathways including dsRNA-dependent protein kinase PKR, IKK β , NF-κ B, and p38 mitogen-activated protein kinase with resultant induction of IL-6, IL-8, and RANTES [110, 142] . Activation of EC by dsRNA may be direct or indirect through the interferon system as discussed above. It has also been reported that dsRNA and virus infections activate EC through binding to TLR3 [143, 144] .

Studies utilizing isolated rabbit tissues and human cultured airway smooth muscle cells suggest that, for RV16, exposure to the virus may have a direct eff ect on smooth muscle cells, resulting in increased contractility to acetylcholine and impaired relaxation to isoproterenol. Th is eff ect is dependent on ICAM-1 and appears to involve an autocrine signaling mechanism including upregulation of production of IL-5 and IL-1 β by the airway smooth muscle itself [145] . A more recent study demonstrated that RV induction of IL-6 and IL-8 was increased in smooth muscle cells from asthmatic compared to normal subjects [146] . Whether rhinovirus reaches airway smooth muscle cells in suffi cient quantity to produce a signifi cant eff ect by this mechanism in vivo is as yet unknown. Th e eff ects of other respiratory viruses on smooth muscle require further investigation.

A variety of leukocytes show changes in number, site of accumulation, and activation state in response to virus infection. Since these cells are also implicated in asthmatic infl ammation of the lower airway they provide potential sites of interaction between the immunopathologies of virus infection and asthma.

Alveolar macrophages are present in large numbers in the lower airway. Th ey make up around 90% of the cells seen in BAL from normal volunteers [28] . Th ey are ideally placed for early phagocytosis of virus particles and are likely to play an important role in the immune response through antigen presentation to T-cells and through the production of cytokines and other mediators. RV has been shown to enter human monocytes and macrophages which express high levels of the major RV receptor ICAM-1. It has not been possible to demonstrate RV replication within alveolar macrophages although low grade productive infection has been shown in the monocyte cell line THP-1 [147] . Replication also occurred in THP-1-derived macrophages but was limited in monocyte-derived macrophages which are relatively resistant to viral replication at least partly because of higher levels of type I interferon production [148] . RV entry into monocytes results in activation and the production of both IL-8 [147] and TNF-α [149] . In monocyte and THP-1derived macrophages RV induction of TNF-α is NF-κ B dependent [148] .

A recent study reported that infectious but not UVinactivated RV-increased TNF-α and IL-8 release by macrophages derived from resected lung tissue. Interestingly, infectious rhinovirus-impaired LPS and lipoteichoic acidinduced TNF-α and IL-8 secretion by macrophages as well as the macrophage phagocytic response to labeled bacterial particles [150] . Th is RV-induced impairment of cytokine responses to bacterial LPS and lipoteichoic acid and of phagocytosis in alveolar macrophages could lead to impairment of antibacterial host defense may have important implications in the pathogenesis of exacerbations of respiratory diseases including both asthma [151] and COPD [152] . In contrast, infection of human monocytes in vitro with infl uenza A causes alterations in structure and activation status and the production of IL-1 β IL-6, TNF-α IFNα , and IFN-β [153] , eff ects dramatically potentiated by subsequent exposure to bacterial LPS.

Dendritic cells are key cells in IFN production, as well as in antigen presentation both of allergens and pathogens with a capacity to induce both primary and secondary immune responses. Th ey may also play a role in the regulation of the type of T-cell-mediated immune response [154] . RV infection has been shown to induce production of the dendritic cell attracting chemokine MIP-3 α [43] and to increase in number in the lung during RSV infection [155] , suggesting they are recruited to the lung during respiratory virus infections. However, they have also been shown to be produced from local precursors during RSV infection [156] . Plasmacytoid dendritic cells are likely protective against infection as they have been shown to limit virus replication in RSV infections, as well as reducing airway infl ammation and airway hyperresponsiveness [157] . In contrast, others have reported induction of the high affi nity IgE receptor on dendritic cells during Sendai virus infection, and linked this with induction of mucus cell metaplasia and airway hyperreactivity [158] . Th ere is thus increasing knowledge of the immunobiology of these cells during respiratory infections but their role in the context of viral exacerbations of asthma remains unclear and further studies are needed.

Bronchial biopsies demonstrate increases in cells positive for CD3, CD4, and CD8 within the epithelium and submucosa of both normal and asthmatic subjects following experimental RV infection [21] and we have recently demonstrated a trend toward increased numbers of lymphocytes in BAL from asthmatic compared to normal subjects ( p ϭ 0.06) [34] . Such increases coincided with peripheral blood lymphopenia, and reductions in blood total lymphocytes and CD8 ϩ T-cells correlated strongly with virus load only in asthmatic subjects [34] suggesting increased recruitment of T-cells to the asthmatic airway may be important in the context of asthma exacerbations. Since T-cells are believed to be key cells in the pathogenesis of asthma the eff ects of viruses on T-cells are of particular importance.

T-cell recruitment into the airway is at least partly under the infl uence of chemokines, including those whose production by EC is upregulated by viruses. Th e nature and the eff ectiveness of the specifi c immune response may be infl uenced by the balance of chemokine production by airway EC. Th is balance may in turn be infl uenced by preexisting chronic infl ammation as found in asthma.

Studies of cloned T-cells suggest that Th 1 and Th 2 cells show diff erential expression of chemokine receptors. Th ere is increased expression of CXCR3 (receptor for IP-10, I-TAC, and Mig) and CCR5 (MIP-1 β ) in human Th 1 cells and increased expression of CCR4 (TARC and MDC) and to a lesser extent CCR3 (eotaxin and MCP-3) in Th 2 cells, with selective migration of cells in response to the appropriate chemokines. CCR1 (RANTES, MIP-1 α , MCP-3) and CCR2 (MCP-1, -2 ,-3, -4) were found on both Th 1 and Th 2 cells [159] . Bronchial biopsies from asthmatics show high levels of expression of CCR4 and significant levels of CCR8 by T-cells [160] .

Increased recruitment of T-cells to the airway as a result of virus-induced chemokine production by EC could amplify preexisting allergic infl ammation. If the asthmatic airway microenvironment infl uences the pattern of chemokine expression following virus infection then this could alter the Th 1/Th 2 balance of the antiviral immune response.

Th e CD4 ϩ T-cell response to virus infection is thought to be of the T-helper 1 (Th 1) type. It is thought that an eff ective antiviral immune response is characterized by the production of type 1 cytokines such as IFN-γ . IFN-γ , in addition to IFN-α , IFN-β , and IFN-λ from monocytes and macrophages, plays a role in establishing an " antiviral state " in neighboring cells. IFN-γ has a complex role in the pathogenesis of asthma. It appears to increase basophil and mast cell histamine release [161] but on the other hand inhibits the expression of type 2 cytokines. Production of IFN-γ is increased in PBMC [162] and in nasal secretions [104] during RV colds and in human and animal models of infl uenza, parainfl uenza, and RSV infection [119, 163, 164] . Th ere are exceptions where the antiviral response exhibits a Th 2 character or a mixture of Th 1/Th 2. In animal models of RSV, diff erent proteins of the virus may induce either Th 1 or Th 2 type responses and priming with such proteins prior to infection with whole virus can infl uence the character, eff ectiveness, and associated immunopathology of the immune response [165] .

Asthma is believed to be characterized by type 2 infl ammation. Many studies have demonstrated mutual inhibition of Th 1 and Th 2 cells [166, 167] . It is therefore possible within an airway with a preexisting type 2 allergic asthmatic microenvironment that there may be inhibition of the normal eff ective type 1 antiviral immune response or that the system may be skewed toward type 2 responses.

Papadopoulos et al . have shown that type 1 responses to RV are defi cient in individuals with asthma [168] . PBMC taken from asthmatics and exposed in vitro to RV show lower levels of IFN-γ and IL-12 and higher levels of IL-4 and IL-10 in culture supernatants than cells from normal subjects. Th e IFN-γ /IL-4 ratio was three times lower in the asthmatic group [168] .

In a study by Gern et al . of experimental RV16 infection in subjects with allergic rhinitis or asthma, the balance of airway Th 1 and Th 2 cytokines in induced sputum induced by viral infection was found to be related to clinical symptoms and viral clearance. Although protein could not be detected in sputum due to the presence of inhibitors of the ELISA assay used, there were increases in mRNA, as determined by semiquantitative RT-PCR, for both IL-5 and IFN-γ . An inverse correlation was demonstrated between the ratio of IFN-γ mRNA to IL-5 mRNA and peak cold symptoms. In addition subjects with RV16 still detectable 14 days after inoculation had lower IFN-γ /IL-5 ratios during the acute phase of the cold than those subjects who had cleared the virus [169] .

We have recently investigated the production of type 1 and type 2 cytokines from BAL cells in asthmatic and normal subjects. We found that production of the type 1 cytokines IL-12 and IFN-γ were suppressed in the asthmatics, while production of the type 2 cytokines IL-4, -5 and, -13 were all increased [34] . Importantly CD4 ϩ T-cell production of IFN-γ was strongly inversely correlated with virus load and reductions in lung function in the asthmatic subjects when they then underwent RV experimental infection, suggesting that CD4 ϩ T-cell production of IFN-γ is protective in the context of RV-induced asthma [34] . Conversely, CD4 ϩ T-cell production of each of IL-4, -5, and -13 was positively correlated with lower respiratory symptom severity, suggesting CD4 ϩ T-cell production of each of IL-4, -5, and -13 are associated with more severe exacerbations. Th ese data are novel and important, but causal roles cannot be established in such human challenge studies. Investigation of the possible causal role of each these cytokines in vivo is now required using the newly developed mouse model [43] .

CD8 ϩ T-cells are important eff ector cells in specifi c cellmediated antiviral immunity. Th ey also demonstrate polarization of cytokine production, the major Tc1 cytokine again being IFN-γ and are believed to regulate CD4 Th 1/ Th 2 balance [170] . In a murine asthma model induction of bystander CD4 ϩ Th 2 responses to ovalbumin resulted in a switch of virus-peptide specifi c lung CD8 ϩ T-cells to production of Tc2 cytokines including IL-5 with, after virus peptide challenge, induction of airway eosinophilia [171] . If this occurs in man it suggests a means whereby CD8 antiviral function could be inhibited at the same time as CD8 amplifi cation of allergic infl ammation through IL-5 induction of airway eosinophilia. Th e role of CD8 ϩ T-cell production of type 1 and type 2 cytokines in virus-induced asthma exacerbations requires investigation. γ δ -TCR ؉ T-cells γ δ -TCR ϩ T-cells are a minor subset of T-cells expressing receptors distinct from the α β receptors found on the majority of T-cells involved in adaptive immunity. Th ere appear to be at least two types of γ δ -TCR ϩ T-cells. Th e fi rst type is found in the lymphoid tissue of all vertebrates and displays highly diversifi ed receptors. Th e second type, intraepithelial γ δ -TCR ϩ T-cells, display receptors of limited diversity. It has been suggested that this second subset recognize molecules expressed only by nearby infected cells. Candidate ligands are heat-shock proteins, MHC class IB molecules and unorthodox nucleotides and phospholipids. Antigen is recognized directly rather than as processed peptide presented by MHC. Recognition of molecules expressed as a consequence of infection rather than pathogen-specifi c molecules themselves would place γ δ -TCR ϩ T-cells at the intersection of innate and adaptive immunity [172] .

However, exaggerated responses to various pathogens and self tissues have been found in studies of mice defi cient in γ δ -TCR ϩ ϩ T-cells rather than defi ciencies in control of pathogens. Such work has suggested that at least some γ δ -TCR ϩ ϩ T-cells have a regulatory role in modulating immune responses [173] , a function consistent with their demonstrated ability to secrete regulatory cytokines when activated.

It has been reported that γ δ -TCR ϩ T-cells are more numerous in the asthmatic airway [174] . A recent study found a greater capacity for production of IL-5 and IL-13 in bronchoalveolar lavage γ δ -TCR ϩ T-cells from asthmatic subjects [175] . If virus infection results in the release of molecules from epithelial cells that activate γ δ -TCR ϩ T-cells in the respiratory mucosa, such cells could provide a source of type 2 cytokines that infl uence the nature of the subsequent immune response. Th e role of γ δ -TCR ϩ T-cells in virusinduced asthma exacerbations requires investigation.

Eosinophils are increased in bronchial epithelium in biopsies taken from normal and asthmatic volunteers following experimental RV infection; in a small study eosinophilic infl ammation persisted for up to 6 weeks in asthmatic subjects [21] and in our recent study eosinophil numbers in the BAL were signifi cantly (threefold) increased in asthmatic compared to normal subjects during the acute RV infection and correlated signifi cantly with reductions in lung function only in the asthmatic subjects [34] . In allergic rhinitis experimental RV infection increases BAL eosinophils following segmental allergen challenge, again persisting for 6 weeks [28] , and increased levels of ECP are found in the sputum of RV-infected subjects [23] and during naturally occurring acute exacerbations of asthma [13] . Eosinophils accumulate in the airway under the infl uence of IL-5, GM-CSF, IL-8, RANTES, and eotaxin [176] . Of these only IL-5 has not been shown to be produced by airway EC in vitro after infection by RV. Expression of RANTES is increased in nasal secretions of children with natural virusinduced asthma [107] . RANTES is upregulated in primary nasal EC cultures by RSV [177] and RV [178] . GM-CSF is important in bone marrow eosinophil production and in eosinophil survival [176] but levels are not increased during viral upper respiratory tract infections [107, 179, 180] . Levels of eotaxin in nasal lavage rise after experimental RV16 infection [181] . Th ese data suggest a pathogenic role for eosinophils in virus-induced asthma. However, a protective role is also possible. In allergic rhinitic subjects, infected with RV after high dose allergen challenge, the severity and duration of cold symptoms were inversely related to the NL eosinophil count prior to infection [32] . Eosinophils may contribute to viral antigen presentation. Eosinophils pretreated with GM-CSF bind RV16 via ICAM-1 and present viral antigen to RV16-specifi c T-cells, inducing proliferation and secretion of IFN-γ [182] . Eosinophils have antiviral actions in parainfl uenza-infected guinea pigs [183] . EDN and ECP have ribonuclease activity and reduce RSV infectivity [184] . Th e role of the eosinophil in the antiviral immune response thus requires further evaluation.

Th ese cells are important sources of infl ammatory mediators, characteristic of allergic infl ammation in asthma. Mast cell basal and stimulated histamine release increases after virus infection [185] . Airway mast cell numbers are upregulated in a rat model of parainfl uenza infection. Several viruses can enhance basophil IgE-mediated histamine release, but the role of this cell in human asthma is controversial.

Mast cells are also important sources of infl ammatory mediators. Th eir function and localization suggest an early interaction with viruses. Leukotriene (LT) C 4 is among the mediators responsible for the late phase of bronchospasm in asthma. During RSV infection increased levels of LTC 4 were found in the nasopharyngeal secretions of infants [186] . Levels correlated well with the symptoms of the disease with concentrations in infants presenting with bronchiolitis being fi vefold higher than in those with only upper respiratory tract symptomatology. Cultured alveolar macrophages can be infected with parainfl uenza virus and respond with an increase in arachidonic acid metabolism. Several of the products of this pathway are known inducers of airway constriction, including LTC 4 , LTD 4 , PGF 2 α , and thromboxanes and/or stimulants of mucous secretion such as PGF 2 α , LTB 4 , and 5-hydroxyeicosatetraenoic acid [187] . RV infection has been shown to induce prostaglandin and LT synthetic enzymes in bronchial biopsies in normal subjects, as well as trends for increased numbers of mast cells ( p ϭ 0.07) bronchoalveolar lavage fl uid cysteinylleukotriene levels ( p ϭ 0.13), but these outcomes have not been studied in asthmatic subjects [188] .

Neutrophils are recruited early during respiratory viral infection in response to the production of IL-8, Gro-α , and ENA-78 by EC and activated neutrophils are a prominent feature of severe asthma. Induced sputum IS in asthmatics and nonasthmatics demonstrates a signifi cant increase in neutrophils at day 4 of a natural cold, correlating with sputum IL-8 [189] . Similar results were obtained in IS taken 2 and 9 days after experimental RV16 infection in asthmatics. Intracellular staining demonstrated an increase in cells positive for IL-8 at day 2 attributable to increased IL-8 positive neutrophils [25] . Th e chemokine IL-8 is a potent chemoattractant for neutrophils but also acts on lymphocytes, basophils, and primed eosinophils. Increased IL-8 has been found in NL from children with natural colds [104] . Experimental RV16 infection of asthmatics resulted in elevated NL IL-8, correlating with cold/asthma symptom scores and histamine PC20 [25] . IS from asthmatics with exacerbations has both elevated IL-8 and neutrophilia [23, 190] . A study of experimental infection in asthmatic children also demonstrated elevated IL-8 and neutrophilia in NL during the acute infection and levels of neutrophil myeloperoxidase correlated with symptom severity [191] . In asthma, exacerbations in asthmatic adults [13] those with virus infection had increased sputum neutrophils and increased neutrophil elastase and more severe clinical disease. Such studies suggest a prominent role for the neutrophil in tissue damage during virus-induced asthma.

Natural killer (NK) cells are an important part of the innate immune response, their function being the elimination of a variety of target cells including virus-infected cells and the modulation of adaptive immunity toward viruses [192] . Cell killing by NK cells may occur through natural killing, antibody-dependent cellular cytotoxicity (ADCC), or apoptotic killing of Fas-positive target cells via membrane bound FasL. Th e ability to directly kill virus-infected cells is regulated by a balance between inhibitory and activating receptors [193] . Killer inhibitory receptors (KIRs), Ig-like receptors that recognize HLA-A, -B, or -C molecules, and the lectin-like CD94/NKG2A receptor that interacts with HLA-E allow NK cells to recognize cells expressing normal self MHC class I [194] . Loss of inhibition occurs if potential target cells have lost class I expression following virus infection or if they display abnormal class I/peptide complexes.

NK cells are rapid and effi cient producers of cytokines such as IFN-γ , important both in early viral infection in the antigen-independent activation of antigen presenting cells such as macrophages, dendritic cells, and epithelial cells, and for biasing the development of CD4 ϩ Th 1 and CD8 ϩ Tc1 cells. Cytokines and chemokines shown to enhance the activities of NK cells in vitro and in vivo include IFN-α /-β , IFN-γ , TNF-α , IL-2, IL-12, IL-15, IL-18, MIP-1 α MIP-1 β , MCP-1, 2, 3, and RANTES. Transforming growth factor (TGF)-β and IL-10 inhibit NK cell activity [195] . Type 2 cytokines may also modulate NK function, increasing NK type 2 activities and decreasing NK type 1 activities. Human NK cells cultured in medium supplemented with IL-4 diff erentiated into NK type 2 cells, secreting IL-5 and IL-13 and when cultured in the presence of IL-12, diff erentiated into NK type 1 cells secreting IL-10 and IFN-γ . IL-4 and IL-13 have also been shown to suppress IL-2induced cytolytic and proliferative activities and IFN-γ production of human NK cells [196] . NK cell production of IL-5 is enhanced by IL-4 and reduced by IL-10 and IL-12 [197] . In a mouse model of asthma, intracellular staining of NK cells has demonstrated IL-5 production and depletion of NK cells resulted in reduced airway eosinophilia [198] .

Th e function of NK cells in the asthmatic airway is as yet unexplored. It may be that, in an airway environment rich in type 2 cytokines, that NK type 1 function and eff ective antiviral activity are inhibited. If this is the case then a key component of the early immune response would be defi cient and viral clearance would be impaired. In addition, if NK type 2 function is favored by the asthmatic microenvironment, production of type 2 cytokines by NK cells in response to virus infection might be one mechanism for amplifi cation of allergic infl ammation. Th ese hypotheses are as yet untested in human studies of experimental virus infection.

An elevated serum total and allergen-specifi c IgE are features of " extrinsic " or atopic asthma. IgE-mediated mechanisms are certainly important in the pathophysiology of extrinsic asthma. Recent studies suggest a similar airway pathology in both extrinsic and " intrinsic " nonatopic asthma [199] where there is an absence of specifi c serum IgE and negative skin prick tests to aeroallergens. It has been suggested that there may be the production of local IgE to as yet unknown environmental allergens in intrinsic asthma.

Upregulation of total IgE or virus-/allergen-specifi c IgE locally or systemically during respiratory virus infection would be expected to contribute to the duration and severity of symptoms of an asthma exacerbation.

Intranasal challenge with RV39 results in an increase in total serum IgE in allergic rhinitic subjects but no increase in preexisting allergen-specifi c IgE [200] . In children with asthma, during infection with infl uenza A there was no change in total IgE but increases were observed in specifi c serum IgE to house dust mite and in ex vivo proliferative and IL-2 responses of lymphocytes challenged with house dust mite allergen [201] . In a study of RSV infection in infants the development of serum RSV-specifi c IgE occurred more frequently in atopics and correlated with clinical wheezing, histamine levels in nasal secretions, and hypoxia [202] . Th ere is no information as yet on the presence of local virus-specifi c IgE in the airway during asthma exacerbations.

Increasing interest in the clinical features and pathogenesis of COPD refl ects the worldwide importance of the disease. More than 14 million patients are aff ected in the United States alone. It is predicted to become the third leading cause of death worldwide by 2020 [203] . National and global initiatives have been launched and management guidelines have been published [204, 205] .

Th e frequency of exacerbations is a major factor in the quality of life of patients with COPD [206] . Th e typical clinical features of an exacerbation include increased dyspnea, wheezing, cough, sputum production, and worsened gas exchange. Although noninfectious causes of exacerbations such as allergy, air pollution, or inhaled irritants including cigarette smoke may be important, acute airway infections are the major precipitants [207] . Th e infection and consequent host infl ammatory response result in increased airway obstruction.

It is likely that two-thirds to three-quarters of COPD exacerbations may be caused by viral infections. In a study of 186 patients rhinoviruses, infl uenza virus, parainfl uenza virus, and coronavirus were signifi cantly associated with COPD exacerbations [208] . Between 60% and 70% of exacerbations are associated with preceding symptoms of a common cold. Th e frequency of exacerbations requiring hospitalization is higher in the winter. One explanation for this could be the increased frequency of respiratory viruses at this time of the year. A recent study of 321 exacerbations in 83 patients with moderate to severe COPD using new diagnostic methods including RT-PCR shows a high incidence of viral infection [209] . Viruses were detected in nasal aspirates at exacerbation in almost 40% of cases. Rhinovirus was the most common, occurring in 58% of cases where a virus was present. Th e presence of virus was associated with increased dyspnea, cold symptoms, and sore throat and with prolonged recovery from exacerbation. Earlier studies relying on serology and virus culture quote lower virus detection rates of 15-20% [208, [210] [211] [212] . Other studies of more severe exacerbations using more comprehensive PCR methods confi rmed the importance of virus infection, with viruses being detected in around 50% of exacerbations [152, 213] . Because these studies all involve sampling relatively late in the course of illness, it is likely that these detection rates underestimate the true importance of virus infections.

Th e role of bacteria in precipitating exacerbations is also somewhat controversial. Bacteria may have a primary role in the development of an exacerbation and/or represent a secondary superinfection of an initial viral process. Various bacterial species are present in the airways of 25-40% of patients, even when the COPD is stable but increased frequency of recovery of bacteria during exacerbations ( ϳ 55%) as well as higher bacterial loads during exacerbations both suggest that they play an important role in a signifi cant number [152, 214, 215] . Signifi cant bacterial infection has been suggested when there is an abundance of neutrophils in the sputum [216] and when the sputum is purulent and green (due to neutrophil myeloperoxidase) [217] . Bacteria may contribute to the pathogenesis of an exacerbation due to increased bacterial loads of bacteria already colonizing diseased airways, however in addition to this, acquisition of new bacterial strains has also been shown to be important, increasing the risk of exacerbation over twofold [218] .

Th e major bacterial organisms associated with COPD exacerbations are nontypable Haemophilis infl uenzae , Streptococcus pneumoniae , and Moraxella (Branhamella) catarrhalis [219, 220] . Mycoplasma pneumoniae and Chlamydia pneumoniae may play a part [221, 222] . Evidence also suggests that in more severe patients with a baseline FEV 1 of 35% predicted or less, gram-negative bacteria especially enterobacteriaceae and pseudomonas play an important part in acute exacerbations [223] .

Recent studies have addressed the role of coinfection with both bacteria and viruses -one study showed this to occur in 25% of exacerbations, and that patients with dual infection had more marked lung function impairment and longer hospitalizations [152] . Another reported that exacerbations with both cold symptoms (a marker of putative viral infection) and a bacterial pathogen, the FEV 1 fall was greater and symptom count was higher than those with a bacterial pathogen alone [224] . Th us even in exacerbations in which viruses are detected, bacteria can also contribute to exacerbation severity.

Although the results of placebo-controlled trials show confl icting results, overall the eff ects of antibiotic treatment also support an etiological role for bacteria in exacerbations in some patients. A meta-analysis of nine studies showed a small overall benefi t when antibiotics were used for COPD exacerbations [225] . Th e largest study included 362 exacerbations in 173 outpatients [216] . Compared with placebo, the rate of symptom resolution and improvement of peak expiratory fl ow during exacerbations was slightly but significantly faster when patients were treated with co-trimoxazole, amoxicillin, or doxycycline. More importantly, treatment failures as defi ned by respiratory deterioration were nearly twice as likely in the placebo group. Benefi t from antibiotics was most evident for patients with most symptoms (dyspnea, increased sputum volume, and sputum purulence).

Guidelines for the use of antibiotics in acute exacerbations of COPD are unclear because of the diffi culties in defi ning the role of bacterial infection in an individual case. Th e American Th oracic Society statement on COPD [205] suggests using antibiotics if there is evidence of infection (fever, leukocytosis, CXR changes) but not all patients with bacterial bronchial infection have fever (this is more common in viral infection or pneumonia) and few have CXR changes. Th e European Respiratory Society recommends antibiotics if the sputum is purulent, using standard antibiotics as fi rst line, and sputum culture if these fail [226] .

Bacterial infection has a defi nite role in the pathogenesis of other chronic lung diseases such as cystic fi brosis and bronchiectasis where bacterial infection is chronic, causing not only acute exacerbations but also infl uencing long-term prognosis [207] .

In these diseases chronic bacterial infection occurs as the host immune response is unable to clear the bacteria, the continuous infection leads to continuous infl ammatory responses and continuous tissue damage [207] . Host and bacterial factors attract and activate neutrophils, which produce proteinases and reactive oxygen species. Lung antiproteinase defenses are overwhelmed. Both proteinase enzymes and reactive oxygen species cause damage to the epithelium, stimulating mucus production and impairing mucociliary clearance. Neutrophil elastase stimulates epithelial cell production of the chemokine IL-8 which attracts further neutrophils and in addition impairs phagocytosis by destroying antibody and cleaving complement receptors from neutrophils and complement components from bacteria. Neutrophils are also stimulated by cigarette smoke.

Identifi cation of bacteria during exacerbation is also associated with increased levels of infl ammatory mediators in BAL and/or sputum. Th ese include reactive oxidant species, IL-8, TNF-α , neutrophil elastase, LTB 4 , and myeloperoxidase and many others. Th ese clearly have potential to cause considerable tissue damage, as well as further recruitment and activation of infl ammatory cells. COPD patients, particularly those at the more severe end of the disease spectrum, may also be chronically colonized by bacteria between exacerbations, bacterial numbers then increasing during exacerbations. In a study using bronchoscopic protected brush specimens [214] 10 of 40 COPD patients were colonized with bacteria when stable. During exacerbations 50% had bacteria present and when present, bacterial numbers were greater. When protected brush specimens were taken during severe acute exacerbations of COPD requiring ventilation [227] bacteria were detected in 50% but it was not possible to distinguish patients more likely to have bacteria on the basis of clinical features or other investigations.

Th e major bacterial pathogens isolated during bronchial infections all form part of the commensal fl ora in the nasopharynx. Bronchial infections occur in patients with abnormal airways with reduced host defenses. Persistence of bacteria within the bronchial tree may come about through toxins that impair mucociliary clearance, enzymes that breakdown local immunoglobulin, products that alter immune eff ector cell function, adherence to mucus and damaged epithelium, or other mechanisms of avoiding immune surveillance [207, 228] .

Bacterial colonization in the stable state represents an equilibrium in which the number of bacteria present in the bronchial tree is contained by the host defenses but not eliminated. During an exacerbation this equilibrium is upset and bacterial numbers increase, inciting an infl ammatory response. Change will usually occur because of a change in the host rather than altered virulence of the bacteria, for example as a result of viral infection.

Exacerbations associated with viral infections also have increased levels of many infl ammatory mediators also found in bacterial exacerbations including TNF-α , IL-8, neutrophil elastase, myeloperoxidase, and LTB 4 . In contrast to bacterial exacerbations where neutrophils and neutrophil products predominate, during a viral exacerbation both neutrophils and eosinophils are present and eosinophil products such as ECP are also increased [152] . Other mediators implicated include ENA-78, RANTES, and endothelin-1 [229] .

It has also been suggested that persistent virus infection contributes to the progression of COPD. In particular, adenovirus appears to persist in a latent form in which viral proteins are produced without replication of complete virus. Such latent infection may amplify lung infl ammation due to cigarette smoke [230] . Adenoviral E1A DNA persists in human lungs from patients with COPD compared with patients of similar age, sex, and smoking history who do not have COPD [231] . Th e E1A protein has been demonstrated in airway epithelial cells from smokers [232] . It is able to amplify many host genes through attachment to the DNA-binding sites of transcription factors [233] . Airway epithelial cells transfected with E1A produce excess infl ammatory cytokines such as IL-8 [234] and surface adhesion molecules such as ICAM-1 [235] after in vitro challenge by an NF-κ B-dependent mechanism [236] .

RSV has been identifi ed in induced sputum from patients with stable COPD. Th ese individuals have a higher plasma fi brinogen and serum IL-6, a higher pCO 2 and increased frequency of exacerbations [209] . Th is suggests either that low grade persistent RSV infection contributes to COPD severity or that patients with more severe COPD are less able to clear RSV from the airway.

Th e immunology of virus infection in COPD is not well understood. Less data is available than for virus infection in asthma since this has not been a major subject of human experimental infection studies. In a small safety study of four patients, inoculation with low dose RV16 resulted in symptomatic colds, viral replication, signifi cant increases in lower respiratory tract symptoms, and reductions in PEF and FEV 1 typical of an acute exacerbation of COPD [237] . Further studies are clearly needed in view of the increasing evidence for a major role for viruses in causing COPD exacerbations.

Currently much of the treatment of infective exacerbations of asthma and COPD is symptomatic, consisting of increased bronchodilators, either short-acting β 2 -agonists in inhaled or intravenous form or anticholinergics or theophyllines, or supportive in the form of oxygen and in severe cases noninvasive or invasive ventilatory measures. Corticosteroids are widely used in inhaled or oral form for their anti-infl ammatory actions. Th e eff ects of corticosteroids are the result of actions at many points in various infl ammatory cascades. Whilst this undoubtedly contributes to their benefi cial eff ects it also results in signifi cant local and systemic side eff ects, in particular if oral steroid treatment is prolonged or frequent. In addition systemic steroids may interfere with the antiviral immune response resulting in reduced viral clearance [238] .

In persistent asthma, control of disease is achieved predominantly with inhaled corticosteroids. Th ere is a role for additional drugs such as long-acting β 2 -agonists and leukotriene antagonists. Th e long-acting β 2 -agonists in particular appear to increase the eff ectiveness of inhaled corticosteroids allowing the dose needed to achieve control to be reduced [239] . Th ere is also evidence that these drugs in combination with inhaled corticosteroids may further reduce exacerbation frequency [240] . Th e leukotriene antagonists appear to be most eff ective in treating or preventing exacerbations in children [241, 242] .

Regular corticosteroid treatment is however only partially eff ective at preventing exacerbations. In adult asthma inhaled steroids reduce exacerbation frequency by only 40% [243] . In school age children inhaled steroids are ineff ective at reducing exacerbation frequency, duration, or severity [244] . In preschool age children with virus-induced wheeze oral steroids are ineff ective even in those with primed eosinophils [245] .

Specifi c antibiotic therapy is available for bacterial infections and is indicated where there is good evidence of such infection or when the exacerbation is severe and bacterial involvement is a possibility.

However, as discussed above the majority of infective asthma exacerbations are of viral rather than bacterial origin and viruses are also common in exacerbations of COPD.

Th e success of vaccination to prevent respiratory virus infections has been limited by signifi cant variation within the major virus types causing disease. Th ere are 102 serotyped strains of rhinovirus and several more that have not been serotyped and no eff ective vaccine has been introduced. A decavalent vaccine [246] developed in the 1970s was ultimately of limited effi cacy. Th e infl uenza viruses display antigenic shift and drift. Vaccines must be modifi ed every 2-3 years to cover the strains prevalent at the time. Vaccination against RSV experienced a major setback in the 1960s when the use of formalin-inactivated virus in young babies resulted in increased disease severity following subsequent virus infection [247] . Eighty percent of vaccinated children required hospitalization when subsequently infected with RSV, as compared to 5% of controls. Th e lungs of two vaccinated children who died contained eosinophilic infi ltrates. It has been suggested that formalin inactivation may have modifi ed epitopes within the RSV G and F surface glycoproteins, resulting in a modifi ed immune response to subsequent infection with enhanced immunopathology [248] . Vaccinated individuals demonstrate a number of diff erences from individuals who have suff ered natural RSV infection including a lack of specifi c mucosal antibodies and defi cient neutralizing and fusion-inhibiting serum antibodies [249] . Th ere are also diff erences in the cell-mediated immune response with some vaccinated individuals demonstrating peripheral eosinophilia and exaggerated lymphocytic proliferative responses to RSV [250] . To protect against RSV infection a successful vaccine would need to provide more eff ective protection than natural infection, which is itself frequently followed by reinfection [251] , and would have to be administered early in infancy to have an eff ect on infant bronchiolitis.

Simple nonspecifi c treatments for the common cold do exist although their effi cacy is debated. Vitamin C and zinc gluconate [252] both may shorten the duration of a cold by 1-2 days. Th e inhalation of humidifi ed hot air provides symptomatic relief [253] . Nasal IFN-α is an eff ective treatment for the common cold [254] but must be given either prior to or shortly after exposure to the virus. It is also expensive and is associated with signifi cant local side eff ects such as bleeding and discharge. Th ese problems have limited its clinical use. However IFN therapy for virus-induced asthma exacerbations may be more useful in view of the defi ciencies identifi ed by recent studies. Further because of the large number of viruses producing similar clinical syndromes, the general antiviral properties of IFNs would provide signifi cant advantage over the use of specifi c antiviral drugs.

Specifi c antiviral agents exist for infl uenza. Amantidine and rimantidine are eff ective against infl uenza A. Th e use of amantidine has been limited by CNS side eff ects such as dizziness and insomnia; fewer such side eff ects are seen with rimantidine. Both drugs are indicated during epidemics for treatment and prophylaxis in high risk groups including asthmatics. Neither is active against infl uenza B. Two neuraminidase inhibitors, zanamivir and oseltamivir, are active against both infl uenza A and B [255] [256] [257] . Th ese agents are eff ective in preventing infection when used as prophylaxis during the infl uenza season and, as treatment, they reduce the duration of illness if started within 36-48 h of the onset of illness. Zanamivir must be given by inhalation whereas oseltamivir can be given orally. Ribavirin is a nucleoside analog active against RSV in vivo and also against infl uenza in vitro . Nebulized ribavirin therapy is licensed for use in hospitalized infants and children in the fi rst 3 days of RSV bronchiolitis. It is however expensive and of unproven benefi t on clinical outcome. Because of its toxicity it is not appropriate for asthma. RSV enriched immunoglobulin was eff ective as prophylaxis for infants at high risk of RSV bronchiolitis [258] but has been superseded by RSV neutralizing monoclonal antibodies [259] .

RV are a major target for drug treatment. It has been estimated that rhinoviruses result in 6-10 colds per year in young children [260] . As yet no eff ective agent is available for clinical use. Capsid-binding/canyon inhibitors block RV binding to host cell receptor (ICAM-1 in the case of the major group). One example in phase 3 clinical trials is pleconaril (Picovir). Th ese drugs can be extremely potent but their clinical usefulness is often limited by toxicity, the need for rapid initiation of therapy and the possible development of resistance. Alternative targets include soluble ICAM-1 which inhibits major rhinovirus infection and conserved viral enzymes such as protein 3D, the RNAdependent RNA transcriptase, protein 2C, the associated ATP-helicase, and the cysteine protease 3C.

Alternative approaches to direct antiviral therapy are suppression of virus-induced infl ammation, or strategies that promote innate or type 1 immune responses in individuals with excessive type 2 responses. Understanding the complexities of the antiviral immune response, in particular how it may be altered in the context of preexisting chronic airway diseases such as asthma is an essential fi rst step. Further work is needed to elucidate the important sites of interaction between the immunological networks of asthma and of virus infection. Greater knowledge is required if we are to identify key targets for therapeutic intervention, the aim of which will be to minimize immunopathology whilst maintaining or enhancing the host anti-viral immune response.

Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Th ree repeat multicountry cross-sectional surveys

Acute asthmatic episodes in children caused by upper respiratory bacteria during colds, with and without bacterial sensitization

Viruses as precipitants of asthma symptoms. II. Physiology and mechanisms

Th e association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children

Th e relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis

Viruses as precipitants of asthmatic attacks in children

Respiratory viral infection and wheezy bronchitis in childhood

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

Personal exposure to nitrogen dioxide (NO 2 ) and the severity of virus-induced asthma in children

Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children

Respiratory viruses and exacerbations of asthma in adults

Viral respiratory tract infection and exacerbations of asthma in adult patients

Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma

Interleukin-10 gene expression in acute virus-induced asthma

Transtracheal aspiration studies in asthmatic patients in relapse with " infective " asthma and in subjects without respiratory disease

Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds

Exacerbations of asthma in adults during experimental rhinovirus infection

Amplifi ed rhinovirus colds in atopic subjects

Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions

Rhinovirus inhalation causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects in vivo

Lower airways infl ammation during rhinovirus colds in normal and in asthmatic subjects

Eff ects of experimental rhinovirus 16 infection on airway hyperresponsiveness to bradykinin in asthmatic subjects in vivo

Experimental rhinovirus 16 infection. Eff ects on cell diff erentials and soluble markers in sputum in asthmatic subjects

Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma

Eff ect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo

Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection

Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects

A common cold virus, rhinovirus 16, potentiates airway infl ammation after segmental antigen bronchoprovocation in allergic subjects

Synergism between allergens and viruses and risk of hospital admission with asthma: Case-control study

Study of modifi able risk factors for asthma exacerbations: Virus infection and allergen exposure increase the risk of asthma hospital admissions in children

Personal exposure to nitrogen dioxide and risk of airfl ow obstruction in asthmatic children with upper respiratory infection

Eff ects of allergic infl ammation of the nasal mucosa on the severity of rhinovirus 16 cold

Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure?

Rhinovirus induced lower respiratory illness is increased in asthma and related to viral load and Th 1/2 cytokine and IL-10 production

Role of viruses and bacteria in acute wheezy bronchitis in childhood: A study of sputum

Detection of rhinovirus RNA in lower airway cells during experimentally induced infection

Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure

Rhinoviruses infect the lower airways

Rhinovirus replication causes RANTES production in primary bronchial epithelial cells

Asthmatic bronchial epithelial cells have a defi cient innate immune response to infection with rhinovirus

Rhinoviruses replicate eff ectively at lower airway temperatures

Basal cells of diff erentiated bronchial epithelium are more susceptible to rhinovirus infection

Mouse models of rhinovirus-induced disease and exacerbation of allergic airway infl ammation

Peak expiratory fl ow changes during experimental rhinovirus infection

Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects

Immune response to viruses

Immune responses to viruses

Type 2 rhinovirus infection of cultured human tracheal epithelial cells: Role of LDL receptor

Complement is activated in the upper respiratory tract during infl uenza virus infection

Rhinovirus 3C protease cleaves the C3 and C5 complement factors

Complement component C3 promotes T-cell priming and lung migration to control acute infl uenza virus infection

Complementdependent neutralization of infl uenza virus by a serum mannosebinding lectin

Mammalian defensins in immunity: more than just microbicidal

Th e time course of the humoral immune response to rhinovirus infection

Prechallenge antibodies: Moderators of infection rate, signs, and symptoms in adults experimentally challenged with rhinovirus type

Prechallenge antibodies moderate disease expression in adults experimentally exposed to rhinovirus strain hanks

Epitope analysis of the T cell response to a complex antigen: Proliferative responses to human rhinovirus capsids

Rhinovirus-specifi c T cells recognize both shared and serotype-restricted viral epitopes

Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects

Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: A longitudinal cohort study

Asthmatic bronchial epithelial cells have a defi cient innate immune response to infection with rhinovirus

Role of defi cient type III interferon-lambda production in asthma exacerbations

Rhinovirus infection induces major histocompatibility complex class I and costimulatory molecule upregulation on respiratory epithelial cells

Disturbances of the ciliated epithelium due to infl uenza virus

Shedding of infected ciliated epithelial cells in rhinovirus colds

Sites of virus recovery and antigen detection in epithelial cells during experimental rhinovirus infection

Respiratory virus infection of monolayer cultures of human nasal epithelial cells

Similar frequency of rhinovirusinfectible cells in upper and lower airway epithelium

Th e major human rhinovirus receptor is ICAM-1

Surface expression of intercellular adhesion molecule-1 on epithelial cells in the human adenoid

Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fl uid during human experimental rhinovirus infection

A biological model to explain the association between human rhinovirus respiratory infections and bronchial asthma

Experimental rhinovirus 16 infection increases intercellular adhesion molecule-1 expression in bronchial epithelium of asthmatics regardless of inhaled steroid treatment

Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity

Cytokines and eosinophilderived cationic proteins upregulate intercellular adhesion molecule-1 on human nasal epithelial cells

Rhinovirus infection of primary cultures of human tracheal epithelium: Role of ICAM-1 and IL-1beta

Interferongamma (IFN-gamma) down-regulates the rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) on human airway epithelial cells

Th 2 cytokines exert a dominant infl uence on epithelial cell expression of the major group human rhinovirus receptor, ICAM-1

ICAM-1 on epithelial cells in allergic subjects: A hallmark of allergic infl ammation

Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial cells of atopic subjects: A mechanism for increased rhinovirus infection?

Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors

Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription

Transcription factors and asthma

Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells

Eff ects of dexamethasone on rhinovirus infection in cultured human tracheal epithelial cells

Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells

Eff ect of desloratadine and loratadine on rhinovirusinduced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells

Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells

Antiviral actions of interferons

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

IL-28, IL-29 and their class II cytokine receptor IL-28R

Viruses and interferon: A fi ght for supremacy

Infl uenza virus NS1 protein counteracts PKRmediated inhibition of replication

Susceptibility to asthma exacerbations: Antiviral immunity and protection against asthma exacerbations

Th e family of IL-10-related cytokines and their receptors: Related but to what extent?

Lambda interferon inhibits hepatitis B and C virus replication

Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells

Viral infection and Toll-like receptor agonists induce a diff erential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells

Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages

Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model

Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages

Interleukin-11: Stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness

Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells

Th e relationship between atopic status and IL-10 nasal lavage levels in the acute and persistent infl ammatory response to upper respiratory tract infection

Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds

Interleukin-11 in respiratory infl ammation

RANTES, macrophage-inhibitory protein 1alpha, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children

Requirement of MIP-1 alpha for an infl ammatory response to viral infection

Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium

Protein kinase R, IkappaB kinasebeta and NF-kappaB are required for human rhinovirus induced proinfl ammatory cytokine production in bronchial epithelial cells

Induction of interleukin (IL)-8 gene expression by respiratory syncytial virus involves activation of nuclear factor (NF)-kappa B and NF-IL-6

Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin

Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro : A potential mechanism of symptom resolution

Kinins are generated in nasal secretions during natural rhinovirus colds

Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat

Detection of tissue kallikrein in the bronchoalveolar lavage fl uid of asthmatic subjects

Inhibition of human bronchial kallikrein in asthma

Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge

Nitric oxide and bronchial reactivity

Nitric oxide in respiratory diseases

Mediators of asthma: Nitric oxide

Nitric oxide and virus infection

Expression and regulation of inducible nitric oxide synthase from human primary airway epithelial cells

Increased nitric oxide in exhaled air of asthmatic patients

Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma

Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease

Exhaled nitric oxide in chronic obstructive pulmonary disease

Cigarette smoke decreases inducible nitric oxide synthase in lung epithelial cells

Altered immune responses in mice lacking inducible nitric oxide synthase

Natural killer cells and nitric oxide

Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects

Nitric oxide inhibits rhinovirus-induced granulocyte macrophage colony-stimulating factor production in bronchial epithelial cells

Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line

Induction and regulation of nitric oxide synthase in airway epithelial cells by respiratory syncytial virus

Replication of respiratory syncytial virus is inhibited in target cells generating nitric oxide in situ

Inhibition of infl uenza virus replication by nitric oxide

Virus-induced airway hyperresponsiveness in guinea pigs is related to a defi ciency in nitric oxide

Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections

Nasal and oral nitric oxide levels during experimental respiratory syncytial virus infection of adults

Respiratory nitric oxide levels in experimental human infl uenza

Molecular pathways in virus-induced cytokine production

Double-stranded RNA induces the synthesis of specifi c chemokines by bronchial epithelial cells

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells

Autocrine cytokine signaling mediates eff ects of rhinovirus on airway responsiveness

Increased proinfl ammatory responses from asthmatic human airway smooth muscle cells in response to rhinovirus infection

Rhinoviruses induce interleukin-8 mRNA and protein production in human monocytes

Rhinovirus replication in human macrophages induces NFkB dependent tumour necrosis factor alpha production

Rhinovirus enters but does not replicate inside monocytes and airway macrophages

Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages

Macrolide antibiotics and asthma treatment

Infections and airway infl ammation in chronic obstructive pulmonary disease severe exacerbations

Role of macrophage cytokines in infl uenza A virus infections

Immunobiology of dendritic cells

Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection

Local CD11c ϩ MHC class II-precursors generate lung dendritic cells during respiratory viral infection, but are depleted in the process

Plasmacytoid dendritic cells limit viral replication, pulmonary infl ammation, and airway hyperresponsiveness in respiratory syncytial virus infection

Induction of high-affi nity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia

Diff erential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th 1s) and Th 2s

Th e C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics

Th e eff ect of T-cell depletion on enhanced basophil histamine release after in vitro incubation with live infl uenza A virus

Peripheral blood mononuclear cell interleukin-2 and interferon-gamma production, cytotoxicity, and antigen-stimulated blastogenesis during experimental rhinovirus infection

Mechanisms of virus induced exacerbations of asthma

Virus-induced airway hyperresponsiveness. Role of infl ammatory cells and mediators

Distinct types of lung disease caused by functional subsets of antiviral T cells

Th e expanding universe of T-cell subsets: Th 1, Th 2 and more

Th e Th 1/Th 2 paradigm

A defective type 1 response to rhinovirus in atopic asthma

Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection

Th 1 and Th 2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus

Virus-specifi c CD8 ϩ cells can switch to interleukin 5 production and induce airway eosinophilia

gammadelta T cells link innate and adaptive immune responses

Compartmentalization gamma/delta T cells and their putative role in mucosal immunity

gamma delta T cells, allergen recognition and airway infl ammation

Cytokine profi le of bronchoalveolar lavagederived CD4( ϩ ), CD8( ϩ ), and gammadelta T cells in people with asthma after segmental allergen challenge

Mechanisms of eosinophil-associated infl ammation

Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells

Rhinovirus replication causes RANTES production in primary bronchial epithelial cells

Nasal lavage cytokines in normal, allergic, and asthmatic school-age children

Nasal cytokine production in viral acute upper respiratory infection of childhood

Experimental common cold increases mucosal output of eotaxin in atopic individuals

Eosinophils bind rhinovirus and activate virus-specifi c T cells

Ovalbumin sensitization changes the infl ammatory response to subsequent parainfl uenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral eff ects

Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity

Virusinduced airway hyperresponsiveness and asthma

Release of leukotriene C4 in respiratory tract during acute viral infection

Infl ammatory mediators of asthma: An update

Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects

Infl ammatory indices in induced sputum: A feasibility study

Prominent neutrophilic infl ammation in sputum from subjects with asthma exacerbation

Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma

Natural killer cells in antiviral defense: Function and regulation by innate cytokines

Human NK-cell receptors

HLA class I-specifi c inhibitory receptors in human T lymphocytes: Interleukin 15-induced expression of CD94/ NKG2A in superantigen-or alloantigen-activated CD8 ϩ T cells

Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections

Diff erentiation of human NK cells into NK1 and NK2 subsets

Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12

IL-5 production by NK cells contributes to eosinophil infi ltration in a mouse model of allergic infl ammation

Th e immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than diff erences

Eff ect of rhinovirus 39 (RV-39) infection on immune and infl ammatory parameters in allergic and non-allergic subjects

Immunomodulation of infl uenza virus infection in the precipitating asthma attack

Th e development of respiratory syncytial virus-specifi c IgE and the release of histamine in nasopharyngeal secretions after infection

Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study

BTS guidelines for the management of chronic obstructive pulmonary disease

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease

Eff ect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease

Th e role of infection in COPD

Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases

Th e role of respiratory viral infections in COPD

Role of infection in chronic bronchitis

Role of infection in chronic bronchitis

Respiratory viral infections in adults with and without chronic obstructive pulmonary disease

Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: A case-control study

Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush

Prediction of tracheobronchial colonization in current cigarette smokers with chronic obstructive bronchitis

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

Bacterial infection in chronic obstructive pulmonary disease

Chemotherapy for chronic bronchitis

Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan

Chlamydia pneumoniae infection in acute exacerbations of COPD

Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function

Eff ect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD

Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis

Optimal assessment and management of chronic obstructive pulmonary disease (COPD)

Characterization of distal bronchial microfl ora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients

Th e biology of bacterial colonization and invasion of the respiratory mucosa

Diagnosis of pathogens in exacerbations of chronic obstructive pulmonary disease

Childhood viral infection and the pathogenesis of asthma and chronic obstructive lung disease

Latent adenoviral infection in the pathogenesis of chronic airways obstruction

Immunodetection of adenoviral E1A proteins in human lung tissue

Promoter targeting by adenovirus E1a through interaction with diff erent cellular DNA-binding domains

Adenovirus E1A upregulates interleukin-8 expression induced by endotoxin in pulmonary epithelial cells

Adenovirus E1A gene dysregulates ICAM-1 expression in transformed pulmonary epithelial cells

Endotoxin-specifi c NF-kappaB activation in pulmonary epithelial cells harboring adenovirus E1A

An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: A pilot study

Oral prednisone therapy in experimental rhinovirus infections

Ligand-independent activation of the glucocorticoid receptor by β 2-adrenergic receptor agonists in primary human lung fi broblasts and vascular smooth muscle cells

Eff ect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Th erapy (FACET) International Study Group

Short-course montelukast for intermittent asthma in children: A randomised controlled trial

Montelukast reduces asthma exacerbations in 2-to 5-year-old children with intermittent asthma

Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial

Eff ect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: Randomised double blind placebo controlled trial

Effi cacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: Randomised controlled trial

Human responses to two decavalent rhinovirus vaccines

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

Respiratory syncytial virus and parainfl uenza virus

Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection

Risk of primary infection and reinfection with respiratory syncytial virus

Zinc gluconate and the common cold. Review of randomized controlled trials

Heated, humidifi ed air for the common cold

Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds

Infl uenza

Zanamivir for the treatment of infl uenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

Zanamivir in the prevention of infl uenza among healthy adults: a randomized controlled trial

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

Viruses as precipitants of asthma symptoms